Potential 100 bagger Biotech missed by the market, page-1080

Hi Pop

Skip to 2:25 of the investor webinar you shared

"how does our drug work... when the body encounters an injury, we already have these specific immune proteins which come to the rescue that repair and regenerate that injury... it is very effective but the body can only make so much of it. So what we have done is isolate the most active site on that protein, and we have a synthetic smaller section of that ... called a peptide. The advantage of making this synthetically is the increase in stability and potency, and there are also very low risks of side effects because it is based on something already occurring in the human body"

Rightly or wrongly, I would make the following observations:
1. To some degree, this peptide/protein already works in the human body and is a part of our immune system. For whatever reason, the body can only produce a finite supply. The thesis is then, if we keep applying the protein to the site will it continue to regenerate, and if so, linearly? exponentially? From the above, my bet is that the protein works, we just don't know to what degree.
2. it seems more absurd that this worked in animal models, as it was designed off something occurring in the human body - although with the optic studies it is mentioned that pig pathology is the most similar to that of humans, I am no animal expert but all I can say is that this was designed for humans, off our immune system. That it worked in in vitro studies makes sense, and now we move into the main event!

Goodluck. I suggest you ask Terry Tadpole for a more balanced view, as from my DD I am heavily invested (within my means) in this stock. But don't trust my research and assumptions, DYOR, I have only been in the stock market a couple of years and 30 yrs old, much the same as Stonk Master